ArticleBritish journal of cancer1994
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer.
Article in British journal of cancer, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 88 citations in OpenAlex.
- c-erb-B2 expression and response to treatment in metastatic breast cancer.Medical oncology (Northwood, London, England) · 2000Trial
- Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.British journal of cancer · 2026Article
- The extracellular domain of Her2 in serum as a biomarker of breast cancer.Laboratory investigation; a journal of technical methods and pathology · 2018Review
- Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.The Indian journal of medical research · 2016Article
- The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.The oncologist · 2015Review
- Challenges in the clinical utility of the serum test for HER2 ECD.Biochimica et biophysica acta · 2012Review
- Serum HER2 levels determined by two methods in patients with metastatic breast cancer.International journal of clinical oncology · 2012Article
- Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.PloS one · 2011Article
- Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood.Methods (San Diego, Calif.) · 2008Review
- Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer.International journal of colorectal disease · 2007Article
- HER-2 gene amplification can be acquired as breast cancer progresses.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Article
- Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma.British journal of cancer · 1997Article
- Prognostic significance of serum c-erbB-2 protein in breast cancer patients.Breast cancer research and treatment · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seventy-nine patients with advanced breast cancer were tested for the presence, in serum, of a 110 kDa soluble, c-erbB-2 fragment. Thirty-nine patients were seropositive. There was no correlation between seropositivity and menopausal status, or with oestrogen status. In addition, no correlation could be found between tissue c-erbB-2 immunostaining for the external domain of the c-erbB-2 receptor and the presence of soluble c-erbB-2 in serum. The presence of serum soluble c-erbB-2, however, had a significant impact on survival of patients with advanced disease, suggesting that this test may become a useful independent prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.